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Abstract
Background: Prenatal screening for Down’s syndrome is performed using biochemical and ultrasound markers measured in
early pregnancy such as the Integrated test using first and second trimester markers. Recently, DNA sequencing methods
have been introduced on free DNA in maternal plasma, yielding a high screening performance. These methods are
expensive and there is a test failure rate. We determined the screening performance of merging the Integrated test with the
newer DNA techniques in a protocol that substantially reduces the cost compared with universal DNA testing and still
achieves high screening performance with no test failures.
Methods: Published data were used to model screening performance of a protocol in which all women receive the first
stage of the Integrated test at about 11 weeks of pregnancy. On the basis of this higher risk women have reflex DNA testing
and lower risk women as well as those with a failed DNA test complete the Integrated test at about 15 weeks.
Results: The overall detection rate was 95% with a 0.1% false-positive rate if 20% of women were selected to receive DNA
testing. If all women had DNA testing the detection rate would be 3 to 4 percentage points higher with a false-positive rate
30 times greater if women with failed tests were treated as positive and offered a diagnostic amniocentesis, or 3 times
greater if they had a second trimester screening test (Quadruple test) and treated as positive only if this were positive. The
cost per women screened would be about one-fifth, compared with universal DNA testing, if the DNA test were 20 times
the cost of the Integrated test.
Conclusion: The proposed screening protocol achieves a high screening performance without programme test failures and
at a substantially lower cost than offering all women DNA testing.
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Introduction
The testing of cell-free DNA circulating in maternal plasma
offers an effective means of screening for Down’s syndrome with
detection rates (proportion of affected pregnancies with positive
results) of 98% or more and false-positive rates (proportion of
unaffected pregnancies with positive results) of about 0.2% or less
[1–7]. At present such DNA testing tends to be expensive (cited as
being charged $795 to $2762 in the United States [6]) and requires
specialist expertise available in only a few laboratories. In about 2–
13% of pregnancies a result cannot be obtained for various reasons
including insufficient fetal DNA in the maternal plasma. These
can be referred to as test failures and tend to be ignored in
describing the efficacy of the test. One study [1] reported 11.5%
(compromised sample, haemolyzed sample, inadequate volume,
failed quality control). Another reported a test failure rate of 3.4%
(0.88% assay failure and 2.50% of samples inadequate [2]). A third
study reported that 16 out of 532 pregnancies (3%) yielded
insufficient fetal DNA and could not be tested and 4 out of 96
Down’s syndrome pregnancies (4.2%; 3 mosaics) yielded an
unidentifiable result as well as 24 out of 426 unaffected
pregnancies (5.6%) suggesting a test failure rate of 7% [3]. A
fourth study reported that in one group 5% did not meet ‘‘QC
criteria’’, but none in a second group of the same size [4]. In a fifth
study based on women undergoing routine screening, results were
not obtained on 4.9% of samples [5]. In a sixth study, based on a
mixture of women with positive conventional screening tests for
Down’s syndrome and women undergoing routine screening,
1.6% failed the quality control criteria [5]. In a seventh study 21
out of 166 samples did not pass the DNA quality test (13%) [7].
We here propose a screening protocol arising from, and
improving on, an idea previously reported [8], that merges
existing methods based on fetal ultrasound measurements and
immunoassays with the newer DNA techniques in a way that
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would substantially reduce the cost compared with the cost of
universal DNA testing and still achieve a high screening
performance, that is, a high detection rate for a low false-positive
rate.
The proposed protocol, which is outlined in Figure 1, uses the
first trimester stage of an Integrated test (late first trimester
measurement of the ultrasound marker nuchal translucency [NT]
and the serum markers free b-human chorionic gonadotropin
[hCG] and pregnancy associated plasma protein-A [PAPP-A] with
maternal age; the Combined test) to determine which women
would receive an automatic DNA sequencing test on the sample
already collected. The automatic application of a second test in
this way can be referred to as ‘‘reflex’’ DNA testing, ie. one
triggered by the result of the first test. All women who do not
receive a DNA test result proceed to have the second part of the
Integrated test which includes the re-use of maternal age and the
NT, free b-hCG and PAPP-A measurements together with early
second trimester measurement of the serum markers alphafeto-
protein [AFP], unconjugated estriol [uE3] and inhibin-A. Typi-
cally the Integrated test uses an hCG (total or the free b)
measurement in the second trimester, but in the proposed protocol
it is measured in the first trimester instead.
The proposal provides a practical solution to the problem that
while DNA testing is an effective screening method it is expensive
and can be done only at a small number of laboratories. We offer a
solution to this by using the existing screening tests based on serum
markers and an ultrasound marker used at a very low false-positive
rate to identify a higher risk group, such that only the higher risk
women need to have the DNA testing. Importantly, this entails
little loss in screening performance.
Methods
Screening performance of the protocol was estimated as follows.
Multivariate Gaussian distribution parameters (means, standard
deviations and correlation coefficients) of the screening markers
from a large cohort study (the Serum Urine and Ultrasound
Screening Study [SURUSS]) [9], revised to incorporate subse-
quent improvements [10], were used to simulate 500,000 Down’s
syndrome pregnancies and 500,000 unaffected pregnancies, each
with a set of marker values (first trimester marker values measured
at 11 completed weeks’ gestation). Each simulated pregnancy was
assigned a maternal age based on the distribution of maternities in
England and Wales from 2006 to 2008 inclusive (the latest
available at the time the study was performed) [11] and the
maternal age-specific odds of an affected livebirth [12–14].
For each simulated pregnancy, a risk of being affected with
Down’s syndrome based on the first stage of the Integrated test
(NT, free b-hCG and PAPP-A) was calculated by multiplying the
maternal age-specific odds of having an affected live birth
(adjusted to early second trimester by multiplying by 1/0.77 to
allow for the general fetal loss in Down’s syndrome pregnancies
from this time in pregnancy until term [14]) by the likelihood ratio
for being affected (for the simulated set of marker values) which
was calculated from the multivariate Gaussian distributions of NT,
free b-hCG and PAPP-A levels in affected and unaffected
pregnancies. The risk cut-offs that yielded initial false-positive
rates of 10%, 20%, 40%, 60%, 80% and 90% were determined. A
DNA result for those with a risk greater than or equal to the
calculated risk cut-off levels was generated. The test failure rate
was taken as 3% (towards the lower range of estimates because in
some instances a repeat sample may be obtained and provide a test
result and these are not considered as test failures in our analyses).
97% were assigned a successfully completed DNA test and 3%
were not. Of those in which DNA testing was assumed to have
been successfully completed, screening performance was taken
from Palomaki et al. [2] as being typically within the range of
estimates, so 98.6% of the simulated Down’s syndrome pregnan-
cies and 0.2% of the simulated unaffected pregnancies were
randomly classified as being screen positive based on DNA
sequencing. For those initially classified low risk, and for those in
whom DNA testing failed, an Integrated test risk of being affected
with Down’s syndrome was calculated re-using the first trimester
markers together with the second trimester markers. Those with
an Integrated test risk greater than 1 in 50 were classified as being
screen positive. Overall detection and false-positive rates were
estimated, and compared with estimates based on all women
having a DNA test. The estimated screening performance was
compared with universal DNA testing based on (i) offering women
with failed tests a diagnostic test, treating them as screen positive,
so yielding a 3.0% false-positive rate, which with the 0.2% test
false-positive rate sums to 3.2% or (ii) offering women a second
Figure 1. Protocol for reflex DNA testing in conjunction with Integrated test screening.
doi:10.1371/journal.pone.0058732.g001
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trimester Quadruple test (AFP, uE3, hCG and inhibin-A; 85%
detection rate for a 5% false-positive rate) [10]. A similar analysis
was done based on using the Combined test (NT, free b-hCG and
PAPP-A) only.
We estimated the cost of the screening protocol per woman as a
multiple of the cost of an Integrated test. If CIT is the cost of an
Integrated test, CDNA the cost of a DNA test, a the proportion of
the Integrated test cost incurred in the first trimester, b the
proportion of the Integrated test cost incurred in the second
trimester and P the proportion of women who have DNA testing
(i.e. the positive rate of the initial stage of the Integrated test), the
cost per woman screened is:-
a|CITð Þz CDNA|Pð Þz b|CIT| 1{Pð Þ½ z 0:03|b|CIT|Pð Þ,
i.e. the cost of the first stage of an Integrated test, plus the cost of a
DNA test in women who have a DNA test plus the cost of the
second stage of the Integrated test in women who do not have a
DNA test plus the cost of the second stage of the Integrated test in
women who have a DNA test, but the test failed.
Because a+b=1, b=1-a, and after dividing throughout by CIT
and rearranging, the cost per woman screened as a multiple of the
cost of the Integrated test is given by the following equation
Cost per woman screened
CIT
~1z 0:97|P| a{1ð Þ½ zP|CDNA
CIT
So if a is 75%, P is 10% and the DNA test is 20 times more
expensive than the Integrated test, the cost per woman screened as
a multiple of the Integrated test cost is
1+[0.9760.16(0.7521)]+2060.1 = 3.0.
A similar analysis was performed using the protocol applied to
the Combined test.
The cost per woman screened as a multiple of the Combined
test is
Cost per woman screened
CCT
~1zP|
CDNA
CCT
Results
Figure 2 is a flow diagram showing an example of the effect of
DNA sequencing in conjunction with the Integrated test in
100,000 pregnancies (including 286 with Down’s syndrome based
on the early second trimester prevalence [11–15]). The first
trimester risk cut-off to achieve an initial false-positive rate of 20%
based on NT, free b-hCG, and PAPP-A was 1 in 1,600. Women
with a risk estimate greater than or equal to this risk cut-off have a
reflex DNA test. A test result is not reported at this stage. The
remaining women continue to have the second part of the
Integrated test. The figure shows 275 (96%) affected and 19,943
(20%) unaffected pregnancies have a reflex DNA test. For 3% of
these women the DNA test fails (8 affected, 598 unaffected). These
women have second trimester markers measured and an
Integrated test risk is reported. Among women who have a
completed DNA test, 263 affected and 38 unaffected pregnancies
have a positive result. Among the women whose DNA test failed
and the women who were not selected for DNA testing after the
first trimester stage of the Integrated test, 8 affected and 44
unaffected pregnancies are positive based on the completed
Integrated test (risk $1 in 50). The overall screening performance
is an estimated detection rate of 95% (271/286) with a false-
positive rate of 0.1% (82/99,714).
Table 1 shows the screening performance of this approach
according to the percentage of women selected for a reflex DNA
test based on the first stage of the Integrated test. As the
percentage increases from 10% to 90% the detection rate increases
from about 92% to 98% and the false-positive rate initially
decreases from 0.11% (10% have a DNA test) to 0.08% (20% have
a DNA test) then increases to 0.20% (90% have a DNA test).
Table 1 also shows the screening performance of routine DNA
Figure 2. Protocol for reflex DNA testing in conjunction with Integrated test screening in which 20% of women at highest risk using
NT, PAPP-A, and free b-hCG (first part of the Integrated test) receive a DNA sequencing test.
doi:10.1371/journal.pone.0058732.g002
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testing without an Integrated test if (i) women with a DNA test
failure have a diagnostic amniocentesis or (ii) women with a DNA
test failure have a second trimester screening Quadruple test, the
two practical options available. In the first case DNA test failures
are regarded as screen-positive and the detection rate is 98.6%
with a false-positive rate of 3.2%. In the second case, in which
women with a failed test have a Quadruple test, the detection rate
is 98.0% with a false-positive rate of 0.3%.
Table 2 shows, in a similar way to Table 1, the cost per woman
screened expressed as a multiple of the cost of an Integrated test.
As the percentage of women having reflex DNA testing increases
from 10% to 90% the cost increases from double to ten-fold if the
cost of the DNA test is ten times the cost of the Integrated test.
Table 2 also shows how the cost per woman screened changes as
the cost of the DNA test decreases. For example if the cost of the
DNA test were 20 times the cost of the Integrated test, and 20% of
women classified as higher risk at the first stage of the Integrated
test, the cost per woman screened would be 5.0 times greater than
the cost of the Integrated test. If the cost of the DNA test were 10
times the cost of the Integrated test, the cost per woman screened
would be 3.0 times greater. The estimates in Table 2 are based on
75% of the cost of the Integrated test being incurred at the first
trimester stage but are robust to different proportions. For
example with the cost being split equally between the first and
second trimesters the cost per woman screened would be 4.9
instead of 5.0 and 2.9 instead of 3.0 times greater in the examples
above.
Figures S1 and S2 illustrate the effect of using the reflex DNA
testing approach with the Combined test in the same way that
figures 1 and 2 do with the Integrated test, and Tables S1 and S2
present the corresponding estimates in the same way as tables 1
and 2. The screening performance is similar to that with the
Integrated test.
Discussion
The reflex DNA testing protocol proposed here, in which the
first part of an Integrated test is used to determine who should
receive a DNA test, has a number of advantages. First, it has a
high screening performance; while the detection rate may be
about five percentage points lower than routine DNA testing, the
false-positive rate is about 30 times lower if DNA test failures are
considered positive and these women have a diagnostic amnio-
centesis, or about 3 times lower if these women have a second
trimester Quadruple test. Second, all women receive a screening
result; there are no failed tests and there is no need to tell some
women that they had a failed DNA test and needlessly cause them
anxiety. Third, the cost of DNA sequencing for the programme is
reduced by 80 or 90%, depending on which of the options is
adopted. The cost of continuing the Integrated test would remain,
which in a public service context is available at the Wolfson
Institute of Preventive Medicine, London, for £35 (about $50), but
at present this is substantially less than all women having a DNA
test. Fourth, the very low false positive rate means that only about
3 per 1000 women screened would need a diagnostic amniocen-
tesis and in about 2 in 3 a Down’s syndrome pregnancy would be
diagnosed. Fifth, such a protocol allows for the screening of other
pregnancy complications such as pre-eclampsia, identified using
immunoassays or heart defects using ultrasound markers.
In our analysis we used the results of Palomaki and colleagues
(DNA test detection rate of 98.6% and false-positive rate of 0.2%
[1]) and a DNA test failure rate of 3%. A sensitivity analysis
showed that our estimated overall detection rate of 94.8% and
overall false-positive rate of 0.08% is robust to reported variations
in the DNA test detection rates, false-positive rates, and test failure
rates. For DNA detection rates between 97.5% and 99.5%, and
false-positive rates between 0.1% and 0.3%, and DNA test failure
rates between 1% and 5%, the overall detection rates were
between 93.6% and 95.8% and the overall false-positive rate
between 0.05% and 0.12%.
In a typical Integrated test free b-hCG is not measured in the
first trimester, but either total or free b-hCG is measured in the
second trimester. In the proposed protocol, the overall screening
performance is marginally better by measuring hCG earlier; if
total hCG were measured in the second trimester and only an NT
and PAPP-A measured in the first trimester, the overall detection
rate would be 93.8% (instead of 94.8%) and the overall false-
positive rate 0.12% (instead of 0.08%) if 20% of women were
selected for a reflex DNA test. There is no advantage in measuring
hCG in both the first and second trimesters. The measurement of
additional markers such as serum placental growth factor, or
ultrasound ductus venosus blood flow or nasal bone would
improve the screening performance of the proposed protocol, but
these are not routinely used, and therefore are not considered
here.
Table 1. Screening performance of reflex DNA tests with the Integrated test according to percentage of women having reflex DNA
test (Integrated test risk cut-off 1 in 50).
Women selected for reflex DNA test after first stage of
Integrated test
Risk cut-off for first stage of
Integrated test Overall screening performance
Detection rate (%) False-positive rate (%)
10% 1 in 630 92.4 0.11
20% 1 in 1600 94.8 0.08
40% 1 in 4900 96.9 0.10
60% 1 in 12000 97.7 0.14
80% 1 in 27000 98.1 0.18
90% 1 in 47000 98.2 0.20
All women have a DNA test (no Integrated test):-
test failures classified as positive 98.6 3.19
test failures have a Quadruple test, risk cut-off 1 in 100 98.0 0.29
doi:10.1371/journal.pone.0058732.t001
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Most of the published studies on DNA sequencing as a
screening test for Down’s syndrome were performed on women
who were, for one reason or another, at higher than average risk,
but this is not a source of bias as the detection rate and false-
positive rate of screening tests using markers that are the
consequence of the disorder are independent of the prevalence
of the disorder.
As experience is gained with the screening protocol proposed in
this paper, and if the cost of DNA testing falls, with a lower rate of
failed tests, DNA testing could be offered to a larger proportion of
pregnancies. At the same time the need for immunoassays and
ultrasound measurements currently used to screen for Down’s
syndrome can be reviewed to assess their value in screening for
other disorders such as pre-eclampsia.
Table 2 provides an indication of the costs of the proposed
protocol with varying proportions having a DNA test. Expressing
cost in multiples of the cost of the Integrated test makes the table
generally applicable, so that, if a 4 to 5 fold greater cost per
woman screened were acceptable, a 20% DNA testing percentage
could be done if the DNA test were 20 times more costly than the
Integrated test, or 40% if 10 times more costly. As can be seen
from figure 2, the marginal cost of detecting the extra 4% (from
95% to 99%) of Down’s syndrome pregnancies that would be
detected if all women had DNA testing rather than adopting the
proposed protocol would be extremely high, requiring about
80,000 extra DNA tests (100,000 – 20,000) for each extra Down’s
syndrome pregnancy detected (if 20% have reflex DNA testing).
This would remain the case unless the cost of a DNA test were
substantially reduced. Collecting plasma samples for DNA testing
that may not be used is, of course, an expense, but a small one
compared with routine DNA testing.
Reflex DNA testing with the Combined test rather than the
Integrated test yields a similar screening performance (see Table
S1) with a similar overall cost (see Table S2). The principal
disadvantage in using reflex DNA testing with the first trimester
Combined test instead of the first stage of the Integrated test is that
it would generate a burden of anxiety in a significant number of
women. This is because a negative Combined test result would be
informed immediately if testing were done at the time of the
ultrasound NT measurement or within a day or two if done in a
central laboratory. However, because many would regard it to be
wrong to artificially delay the reporting of a negative screening
result, a ‘‘positive’’ would trigger a DNA test that would take 1–2
weeks, so if women did not receive a prompt result they would
realize that they were in a higher risk category. If 20% were
selected for a DNA test, as shown in Figure S2, this would apply to
20% of women in the population. If, however, as we suggest DNA
testing were conducted together with the Integrated test the
corresponding proportion would be substantially less than 1%.
A feature of the proposed screening protocol is that it applies
equitably to all pregnant women with the cost averaged over all
women screened, regardless of who has a DNA test. This is a
practical approach in the context of a screening programme,
which is the appropriate way of delivering the service to a
population.
Our proposed protocol could usefully be linked to interpretive
software that would automatically modify the proportion of
women selected for reflex DNA testing and provide the
appropriate risk cut-off to achieve this. Also, all women who have
a DNA test could receive an estimate of the risk of having a
Down’s syndrome pregnancy, based on a combination of the DNA
test result and the first stage of the Integrated test, so the results
would be quantitative and not simply be based on a qualitative
DNA result. In deriving this risk, the DNA result could be adjusted
for relevant factors such as the fetal DNA fraction and maternal
weight.
In summary, the proposed protocol combines current screening
methods with the newer DNA sequencing methods to provide a
cost effective strategy for all pregnant women with a very high
level of efficacy and safety.
Supporting Information
Figure S1 Protocol for reflex DNA testing in conjunction
with Combined test screening.
(TIF)
Figure S2 Protocol for reflex DNA testing in conjunction
with Combined test screening in which 20% of women at
highest risk using the Combined test receive a DNA
sequencing test.
(TIF)
Table S1 Screening performance of reflex DNA tests
with the Combined test according to percentage of
women having reflex DNA test. (Combined test risk cut-off
1 in 50 for DNA test failures).
(DOCX)
Table S2 Illustration of the cost per woman screened
according to the cost of the DNA test, expressed as a
multiple of the cost of a Combined test, and the
Table 2. Illustration of the cost per woman screened according to the cost of the DNA test, expressed as a multiple of the cost of
an Integrated test, and the proportion of women who have a DNA test (i.e. positive based on a the first trimester stage of the
Integrated test, 75% of the cost of the Integrated test incurred in the first trimester).
Women selected for reflex DNA test after first stage of
Integrated test DNA test cost as a multiple of Integrated test cost
2.5 5 10 20 40
10% 1.2 1.5 2.0 3.0 5.0
20% 1.5 2.0 3.0 5.0 9.0
40% 1.9 2.9 4.9 8.9 17
60% 2.4 3.9 6.9 13 25
80% 2.8 4.8 8.8 17 33
90% 3.0 5.3 9.8 19 37
doi:10.1371/journal.pone.0058732.t002
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proportion of women who have a DNA test (i.e. positive
based on the Combined test).
(DOCX)
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